The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC

约翰霍普金斯大学转化免疫工程 (JH-TIE) BTRC

• 批准号: 9790435
• 负责人: JONATHAN P SCHNECK
• 金额: $ 170.74万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9790435
• 关键词: Advisory Committees; Antigen-Presenting Cells; Autoimmune Diseases; Back; Biocompatible Materials; Biological Response Modifier Therapy; Biology; Biomedical Engineering; Capital; Cell Therapy; Cells; Cellular immunotherapy; Clinic; Clinical; Collaborations; Communicable Diseases; Communication; Communities; Cytotoxic T-Lymphocytes; Development; Devices; Disease; Educational Curriculum; Educational workshop; Engineering; Event; Foundations; Funding; Gene Transfer; Generations; Genetic; Geography; Goals; Healthcare; Immune; Immune system; Immunologist; Immunology; Immunosuppressive Agents; Immunotherapy; Industrialization; Inflammatory; Infrastructure; Institutes; International; Jordan; Knowledge; Lead; Libraries; Life; Malignant Neoplasms; Metabolic; Methodology; Microscopy; Mission; Modification; Neurodegenerative Disorders; Nomenclature; Online Systems; Outcome; Participant; Pathology; Population; Process; Protocols documentation; Public Health; Publications; Regenerative Medicine; Regulatory T-Lymphocyte; Research; Research Personnel; Resources; Savings; Scientific Advances and Accomplishments; Scientist; Seasons; Services; Students; T-Lymphocyte; Techniques; Technology; Therapeutic; Tissue Engineering; Training; Training Programs; Translational Research; Translations; United States National Institutes of Health; Work; base; cancer therapy; cellular engineering; certificate program; conflict resolution; design; extracellular; graduate student; immunoengineering; improved; in vivo; infectious disease treatment; inhibitor/antagonist; innovation; leadership development; nano; nanobiotechnology; next generation; novel; oncology; outreach; particle; posters; regenerative therapy; research and development; scale up; small molecule; symposium; technology research and development; technology/technique; therapy development; tool; treatment optimization; web site

Overall – Summary Research in immunology has created stunning scientific advances that have the potential to revolutionize regenerative medicine, infectious disease, autoimmune disorders, neurodegenerative disease, and cancer. Yet, innovations remain in the lab, not realizing their clinical potential. Immunologists develop therapies that focus on fundamental mechanistic biology but lack tools to optimize therapies. Engineers bring a quantitative approach and highly optimized devices and treatments, but often avoid the immune system entirely, rather than trying to harness it. A profound gap exists between engineering and immunology, one that has held back life-saving innovations from reaching the clinic. The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC will serve as a thought leader and collaborative hub for immunoengineering research. JH-TIE will bring together the worlds of engineering and immunology, leading the research and development of transformative cancer therapies and regenerative medicine. JH-TIE's goals include: • Develop products, techniques, and methodologies to streamline the stimulation and expansion of functional T cells to provide a greater number of therapeutic cells faster and with greater proliferative potential, including a GMP-compliant batching methodology for scale-up; • Develop new enabling technologies, techniques, and products for more effective stimulation and modification of immune cells, including via biomaterials-based gene transfer and use of novel small molecule activators and inhibitors; • Develop new biotherapeutics for cellular engineering to increase T cell efficacy in vivo, including increased robustness of cytotoxic T cells against immunosuppressive counter-effects as well as complementary technology to engineer regulatory T cells for potential use for autoimmune diseases; • Expand the reach of immunoengineering principles by offering training courses, seminars, and curricula for researchers, industrial practitioners, clinicians, and students, including a new certificate program in immunoengineering for graduate students; • Advance the field of immunoengineering by hosting conferences, short courses, and other targeted offerings; • Serve as an interface and liaison for communities of engineers, immunologists, and other stakeholders. Three Technology Research and Development (TR&D) projects that will serve as a foundation for the JH-TIE center. Each TR&D is designed to deliver a technical service platform in support of a diverse community of end users. JH-TIE will provide training and dissemination of key technologies and techniques developed to collaborators and the broader research community. Collaborative and service projects are proposed in conjunction with this effort to broaden the technologies' impact. JH-TIE will expand on standard dissemination by hosting local workshops and classes, international seminars, and web-based tutorials. The JH-TIE will lead a paradigm shift and grow the field of immunoengineering. JH-TIE will achieve this through world-class research and by broadly engaging a diverse set of stakeholders. Together, these efforts will advance the field of immunoengineering, enabling new cell-based and regenerative therapies to reach the clinic, and training a generation of new immunoengineering practitioners.

总体--摘要 免疫学的研究创造了惊人的科学进步，有可能带来革命性的 再生医学、传染病、自身免疫性疾病、神经退行性疾病和癌症。 然而，创新仍然留在实验室，没有实现它们的临床潜力。免疫学家开发的治疗方法是 专注于基本的机械生物学，但缺乏优化治疗的工具。工程师们带来了一个量化的 方法和高度优化的设备和治疗，但往往完全避免免疫系统，而不是 而不是试图驾驭它。工程学和免疫学之间存在着深刻的鸿沟，这一鸿沟一直存在 使挽救生命的创新成果无法应用于临床。 约翰霍普金斯翻译免疫工程(JH-TIE)BTRC将作为思想领袖 和免疫工程研究的协作中心。JH-Tie将把世界各地的 工程和免疫学，领导变革性癌症疗法和 再生医学。JH-Tie的目标包括： ·开发产品、技术和方法，以简化激励和扩展 功能T细胞提供更多数量的治疗细胞更快和更 增殖潜力，包括符合GMP的批次方法以扩大规模； ·开发新的使能技术、技术和产品，以实现更有效的刺激和 免疫细胞的修饰，包括通过基于生物材料的基因转移和使用新的小分子 分子活化剂和抑制剂； ·为细胞工程开发新的生物疗法，以提高体内T细胞的效力，包括 增强细胞毒性T细胞对免疫抑制的反作用以及 设计调节性T细胞的补充技术，以潜在用于自身免疫性疾病； ·通过提供培训课程、研讨会和 面向研究人员、工业从业者、临床医生和学生的课程，包括新证书 研究生免疫工程课程； ·通过举办会议、短期课程和其他有针对性的活动，推动免疫工程领域的发展 供品； ·作为工程师、免疫学家和其他人员社区的接口和联络人 利益相关者。 将作为JH-TIE基础的三个技术研究和开发(TR&D)项目 中间。每个研发都旨在提供一个技术服务平台，以支持不同的终端社区 用户。 JH-Tie将为合作者提供关键技术和开发技术的培训和传播 以及更广泛的研究界。协同项目和服务项目是与此相结合提出的 努力扩大技术的影响。JH-Tie将通过主办本地节目来扩大标准传播 讲习班和课程、国际研讨会和基于网络的教程。 JH-TIE将引领范式转变，并发展免疫工程领域。JH-Tie将实现这一目标 通过世界级的研究和广泛接触不同的利益攸关方。总而言之，这些努力 将推动免疫工程领域的发展，使基于细胞的新疗法和再生疗法能够达到 临床，并培养一代新的免疫工程从业者。